STOCK TITAN
  1. Home
  2. Sec-filings
  3. OGEN
  4. [Form 4] Oragenics Inc. Insider Trading Activity

Oragenics Insider Odyssey Health Exits Position with Two Share Sales

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Key takeaways from Oragenics Inc. (OGEN) Form 4:

  • Reporting person: Odyssey Health, Inc., designated as a 10% owner.
  • Two open-market sales of common stock were disclosed.
  • 17 Jun 2025: 2,000 shares sold at $4.46.
  • 18 Jun 2025: 5,044 shares sold at $4.26.

After completing these transactions, Odyssey Health reports 0 shares of Oragenics common stock remaining, indicating a full divestiture of its previously reportable stake. All transactions were coded “S” (sale) and were executed directly; no derivative securities or additional transactions were reported.

Positive

  • None.

Negative

  • 10% owner Odyssey Health sold 7,044 shares over two days and now holds zero OGEN shares, representing a full exit.
  • No insider purchases or positive insider activity were reported in this filing.

Insights

TL;DR: 10% owner Odyssey Health liquidates entire OGEN stake—7,044 shares—via two sales at $4.46 and $4.26; negative insider signal.

Odyssey Health’s Form 4 shows back-to-back sales totaling 7,044 shares. Post-sale beneficial ownership is now zero, meaning the entity is no longer an insider under the 10% threshold. While the filing offers no motive, a complete exit by a significant holder often raises investor concern about near-term prospects or valuation. No offsetting insider purchases or derivative activity appear in the filing, reinforcing the negative read-through for sentiment-driven investors.

TL;DR: Complete divestiture ends Odyssey Health’s Section 16 reporting duty; material change in insider ownership structure.

The Form 4 indicates Odyssey Health is relinquishing its insider status by reducing holdings to zero. Such shifts can alter governance dynamics: proxy influence, voting power, and continued disclosure obligations all diminish once the 10% threshold is crossed in reverse. No 10b5-1 plan is referenced, so the sales appear discretionary. Given the magnitude relative to total holdings (100% disposition), the development is impactful for monitoring future ownership concentration and potential shifts in strategic control.

Insider Odyssey Health, Inc.
Role 10% Owner
Sold 7,044 shs ($30K)
Type Security Shares Price Value
Sale Common Stock - OGEN 5,044 $4.26 $21K
Sale Common Stock - OGEN 2,000 $4.46 $9K
Holdings After Transaction: Common Stock - OGEN — 0 shares (Direct)
Footnotes (1)
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Odyssey Health, Inc.
(Last) (First) (Middle)
2300 WEST SAHARA AVENUE,
SUITE 800 - #4012
(Street)
LAS VEGAS NV 89102
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ORAGENICS INC [ OGEN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock - OGEN 06/17/2025 06/17/2025 S 2,000 D $4.46 5,044 D
Common Stock - OGEN 06/18/2025 06/18/2025 S 5,044 D $4.26 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Christine M. Farrell, CFO 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many Oragenics (OGEN) shares did Odyssey Health sell?

Odyssey Health sold 7,044 shares in total.

At what prices were the OGEN shares sold?

Shares were sold at $4.46 on 17 Jun 2025 and $4.26 on 18 Jun 2025.

What is Odyssey Health's remaining stake in Oragenics after the transactions?

Following the sales, Odyssey Health reports 0 shares, indicating a complete divestiture.

Were any derivative securities involved in the Form 4 filing?

No. The filing lists no derivative security transactions or holdings.

Does Odyssey Health remain a Section 16 insider after these sales?

With beneficial ownership now at 0 shares, Odyssey Health is no longer a 10% owner and may cease Section 16 insider status.